Everest Organics starts API production for Merck anti-COVID pill
Manufacturer starts development of API for molnupiravir, which is set to become world’s first oral treatment against coronavirus
India’s Everest Organics has started manufacturing the active pharmaceutical ingredient for Merck & Co’s investigational antiviral pill, molnupiravir, to treat mild to moderate COVID-19, the API manufacturer said in a filing to the Bombay Stock Exchange.
“After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, Posaconazole, Everest Organics is on its path of expansion of this portfolio and hence has further developed an additional COVID-19 treatment API in that segment,” said Srikakarlapudi Sirisha, Chief Executive Officer, New Product Development at Everest Organics.
The company said in the filing that the drug was being developed at lab scale.
Earlier this month, Merck and partner Ridgeback Biotherapeutics announced that in a Phase 3 trial, molnupiravir reduced the risk of hospitalization and death by around 50% for patients with mild or moderate cases of COVID-19. The APl is administered orally and works by inhibiting the replication of the coronavirus inside the body.
The two companies have submitted an Emergency Use Application for the pill to the US Food and Drug Administration, which if approved would make it the world’s first oral antiviral treatment for COVID-19.
Everest Organics has an API facility in Hyderabad, India and manufactures and exports APIs to more than 40 countries as well as serving domestic demand.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.